Grossman, Murray http://orcid.org/0000-0002-7447-6218
Seeley, William W.
Boxer, Adam L. http://orcid.org/0000-0002-1215-5064
Hillis, Argye E.
Knopman, David S. http://orcid.org/0000-0002-6544-066X
Ljubenov, Peter A.
Miller, Bruce
Piguet, Olivier
Rademakers, Rosa
Whitwell, Jennifer L.
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
van Swieten, John C.
Article History
Accepted: 12 June 2023
First Online: 10 August 2023
Competing interests
: H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). A.L.B. has received financial support from NIH, the Association for Frontotemporal Degeneration, the Bluefield Project, the Rainwater Charitable Foundation, Regeneron, Eisai and Biogen; and has served as a paid consultant for AGTC, Alector, Amylyx, AviadoBio, Arkuda, Arrowhead, Arvinas, Eli Lilly, Genentech, LifeEdit, Merck, Modalis, Oligomerix, Oscotec, Transposon and Wave. D.S.K. serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network Treatment Unit study; served on a Data Safety monitoring Board for a tau therapeutic for Biogen (until 2021) but received no personal compensation; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California; has served as a consultant for Roche, Samus Therapeutics, Magellan Health, Biovie and Alzeca Biosciences but receives no personal compensation; attended an Eisai advisory board meeting for lecanemab on December 2, 2022, but received no compensation; and is an unpaid coinvestigator in an Alector trial for persons with GRN mutations. R.R. received financial support from NIH; is a member of the Scientific Advisory Board of Arkuda Therapeutics; and receives invention royalties from a patent related to progranulin. W.W.S. serves as a paid consultant to Biogen Idec and has received grant support from NIH, the Association for Frontotemporal Degeneration, the Bluefield Project, the Rainwater Charitable Foundation, and the Chan-Zuckerberg Initiative. J.L.W. and A.E.H. received grant support from the NIH. B.M. has received grant support from NIH, the Bluefield Project, and the Rainwater Charitable Foundation; has received royalties from books published by Cambridge University Press, Elsevier, Inc., Guilford Publications, Inc., Johns Hopkins Press, Oxford University Press and Taylor & Francis Group; has received honorarium for serving as a member of the Scientific Advisory Board of the Alzheimer’s Disease Research Center (ADRC) at Massachusetts General Hospital, Stanford University, and the University of Washington; and has received consulting fees from Genworth. P.A.L. receives research search support from NIH/NIA and the Alzheimer’s Association Part the Cloud Partnership; is the FDA IND sponsor for a clinical trial of a drug supplied by Biohaven; has served as a clinical site primary investigator for trials sponsored by Woolsey, Alector, Transposon, and AbbVie; and currently serves as a clinical site sub-investigator for clinical trials sponsored by Lilly, Eisai and Biogen.